MedTrace Logo

Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

NCT04779242 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 670

Last updated 2025-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.

Conditions

  • Community-acquired Pneumonia
  • Bacterial Pneumonia

Interventions

DRUG

Omadacycline

IV for injection, oral tablets

DRUG

Moxifloxacin

IV solution, oral tablets

Sponsors & Collaborators

  • Paratek Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Amy Manley · Paratek Pharmaceuticals Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-25
Primary Completion
2024-03-27
Completion
2024-03-27
FDA Drug
Yes

Countries

  • Bulgaria
  • Croatia
  • Georgia
  • Hungary
  • Poland
  • Russia
  • Serbia
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04779242 on ClinicalTrials.gov